biote Corp. (NASDAQ:BTMD – Get Rating) CFO Samar Jagat Kamdar acquired 13,000 shares of biote stock in a transaction dated Monday, January 9th. The shares were bought at an average price of $3.00 per share, for a total transaction of $39,000.00. Following the transaction, the chief financial officer now owns 13,000 shares of the company's stock, valued at $39,000. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

biote Stock Up 11.9 %

Shares of NASDAQ BTMD traded up $0.40 during midday trading on Tuesday, reaching $3.75. 142,380 shares of the stock traded hands, compared to its average volume of 327,212. The company's 50 day moving average is $3.96 and its 200 day moving average is $4.11. biote Corp. has a one year low of $2.00 and a one year high of $10.52.

biote (NASDAQ:BTMD – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.23). The business had revenue of $41.97 million for the quarter, compared to analyst estimates of $41.86 million. As a group, equities analysts predict that biote Corp. will post 0.78 EPS for the current fiscal year.

Analyst Ratings Changes

Institutional Investors Weigh In On biote

Large investors have recently added to or reduced their stakes in the stock. Pitti Group Wealth Management LLC purchased a new position in shares of biote in the 3rd quarter worth approximately $105,000. Prelude Capital Management LLC bought a new stake in biote in the second quarter worth $250,000. Cowen AND Company LLC purchased a new position in biote during the second quarter worth $49,000. Millennium Management LLC bought a new position in biote during the second quarter valued at $445,000. Finally, Creative Planning purchased a new stake in shares of biote in the second quarter valued at $44,000. 3.81% of the stock is owned by institutional investors.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

See Also

• Get a free copy of the StockNews.com research report on biote (BTMD)
• Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
• Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
• The WD-40 Company Is Ready To Rebound, But Will It?
• Skechers Not Nike Is The Sneaker Stock to Own for 2023
• Can The Rally In e.l.f. Beauty Stock Continue?

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.